The pharmacokinetics of methadone and its metabolites in neonates, infants, and children

Paediatric Anaesthesia

Volumn 24, Issue 6, 2014, Pages 591-601

  Ward, Robert M ^a   Drover, David R ^b   Hammer, Gregory B ^b   Stemland, Christopher J ^c   Kern, Steve ^a,d,g   Tristani Firouzi, Martin ^a   Lugo, Ralph A ^d,h   Satterfield, Kristin ^e,i   Anderson, Brian J ^f  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e Department of Pharmaceutics University of Utah College of Pharmacy ^*  (United States)

^f STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^g BILL AND MELINDA GATES FOUNDATION   (United States)

^h EAST TENNESSEE STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

analgesia; modeling; opioid; pediatrics; pharmacodynamics; pharmacokinetics

Indexed keywords

DRUG METABOLITE; METHADONE; NARCOTIC ANALGESIC AGENT;

ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; ENANTIOMER; HEART SURGERY; HUMAN; INFANT; NEWBORN; PEDIATRIC SURGERY; PHARMACOKINETICS; PRIORITY JOURNAL; RACEMIC MIXTURE; STEREOISOMERISM; ADOLESCENT; AGING; ALGORITHM; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECTS; ELECTROCARDIOGRAPHY; FEMALE; MALE; METABOLISM; PRESCHOOL CHILD;

ADOLESCENT; AGING; ALGORITHMS; ANALGESICS, OPIOID; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHADONE; STEREOISOMERISM;

EID: 84900507506     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/pan.12385     Document Type: Article

References (25)

1. Sharma A, Tallchief D, Blood J, et al,. Perioperative pharmacokinetics of methadone in adolescents. Anesthesiology 2011; 115: 1153-1161.
2. Rosen TS, Pippenger CE,. Pharmacologic observations on the neonatal withdrawal syndrome. J Pediatr 1976; 88: 1044-1048.
3. Mack G, Thomas D, Giles W, et al,. Methadone levels and neonatal withdrawal. J Paediatr Child Health 1991; 27: 96-100.
4. Yang F, Tong X, McCarver DG, et al,. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2006; 33: 485-518.
5. Stemland CJ, Witte J, Colquhoun DA, et al,. The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion. Pediatr Anesth 2013; 23: 51-57.
6. Clavijo C, Bendrick-Peart J, Zhang YL, et al,. An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 874: 33-41.
7. Himes SK, Goodwin RS, Rock CM, et al,. Methadone and metabolites in hair of methadone-assisted pregnant women and their infants. Ther Drug Monit 2012; 34: 337-344.
8. Lux RL, Sower CT, Allen N, et al,. The application of root mean square electrocardiography (RMS ECG) for the detection of acquired and congenital long QT syndrome. PLoS ONE 2014; 9: e85689.
9. Kharasch ED, Hoffer C, Whittington D, et al,. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004; 76: 250-269.
10. Holford NHG,. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-332.
11. Anderson BJ, Meakin GH,. Scaling for size: some implications for paediatric anaesthesia dosing. Paediatr Anaesth 2002; 12: 205-219.
12. Anderson BJ, Holford NH,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332.
13. Hill AV,. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Ph\ol 1910; 14: iv-vii.
14. Efron B,. Bootstrap methods: another look at the jackknife. Ann Stat 1979; 7: 1-26.
15. Post TM, Freijer JI, Ploeger BA, et al,. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008; 35: 185-202.
16. Karlsson MO, Savic RM,. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 17-20.
17. Hines RN,. Developmental expression of drug metabolizing enzymes: Impact on disposition in neonates and young children. Int J Pharm 2012; 452: 3-7.
18. Stevens JC, Hines RN, Gu C, et al,. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003; 307: 573-582.
19. Foster DJ, Somogyi AA, White JM, et al,. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 2004; 57: 742-755.
20. Dale O, Sheffels P, Kharasch ED,. Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol 2004; 58: 156-162.
21. Grassin-Delyle S, Buenestado A, Naline E, et al,. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther 2012; 134: 366-379.
22. Schwartz PJ, Paul AG Jr, Stramba-Badiale M, et al,. Report from the task force of the European Society of cardiology for the interpretation of the neonatal electrocardiogram. Cardiol Young 2002; 12: 592-608.
23. FDA. Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs 10903 New Hampshire Avenue, Silver Spring, MD 20993 US Department of Health & Human Services, 2005.
24. Gourlay GK, Willis RJ, Wilson PR,. Postoperative pain control with methadone: influence of supplementary methadone doses and blood concentration-response relationships. Anesthesiology 1984; 61: 19-26.
25. Inturrisi CE, Portenoy RK, Max MB, et al,. Pharmacokinetic- pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther 1990; 47: 565-577.